Posts tagged ‘Erlotinib’
April 27th, 2011
The results from the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer elimination) clinical trial in non-small cell lung cancer (NSCLC) undertaken at MD Anderson Cancer Center were recently published in the new AACR journal Cancer Discovery.
The BATTLE study is a landmark in that tumor biopsies were done in “real time” with adaptive randomization to erlotinib, vandetanib, erlotinib plus bexarotene or sorafenib based on relevant molecular biomarkers from the needle biopsy specimens.
Sally Church who did her doctoral research on the early detection of lung disease, has does an excellent job on Pharma Strategy Blog of reviewing the findings from this landmark clinical trial. She discusses the latest results presented by Dr Waun ki Hong in the plenary session at the recent AACR annual meeting in Orlando.
Using Storify to integrate multimedia about the BATTLE trial, Sally explains why this is a ground breaking study. You can read more on Pharma Strategy Blog.
March 25th, 2011
Sally Church, PhD our oncology new products expert, is passionate about making a difference to the lives of patients with cancer. She channels her many talents and energies into helping pharma and biotech companies assess the best targets for their new products. It’s a job that requires science, marketing strategy and commercial awareness; a unique blend of skills.
Sally’s recent post on Pharma Strategy Blog entitled “Accelerated approval and cancer drugs” considers how best to bring new cancer drugs to market? Should promising oncology new products go from phase 2 clinical trials to market without the need for a large and expensive phase 3 registration study? If so, what happens when the data doesn’t pan out as happened with Roche/Genentech’s bevacizumab (Avastin) in breast cancer?
You can read more about Sally’s thoughts on Pharma Strategy Blog.